Method for the simultaneous determination of losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry

被引:39
作者
Iwasa, T [1 ]
Takano, T [1 ]
Hara, K [1 ]
Kamai, T [1 ]
机构
[1] Banyu Pharmaceut Co Ltd, Res & Dev Labs, Menuma, Saitama 3600214, Japan
来源
JOURNAL OF CHROMATOGRAPHY B | 1999年 / 734卷 / 02期
关键词
losartan; EXP-3174;
D O I
10.1016/S0378-4347(99)00358-8
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A liquid chromatography-electrospray ionization tandem mass spectrometric method was developed for the simultaneous determination of losartan and its major active metabolite, EXP-3174, in human plasma. The two analytes and the internal standard (DuP-167) were extracted from plasma under acidic conditions by using solid-phase extraction cartridges containing a sorbent of copolymer, poly(divinylbenzene-co-N-vinylpyrrolidone). The analytes were separated by LC equipped with a reversed-phase C-18 column, and introduced into the mass spectrometer via the electrospray ion source with pneumatically-assisted nebulization. For LC-MS-MS samples, an isocratic mobile phase consisting of [0.1% triethylamine-0.1% acetic acid (pH 7.1)]-acetonitorile (65:35, v/v) was used, and the assay was monitored for the negative fragment ions of the analytes. The method demonstrated linearity from 1 to 1000 ng/ml for both losartan and EXP-3174. The Limit of quantification for both compounds in plasma was 1 ng/ml. This assay method may be useful for the measurement of levels of the two compounds in clinical studies of losartan. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:325 / 330
页数:6
相关论文
共 9 条
[1]   ANGIOTENSIN-II RECEPTOR BLOCKADE - AN INNOVATIVE APPROACH TO CARDIOVASCULAR PHARMACOTHERAPY [J].
EBERHARDT, RT ;
KEVAK, RM ;
KANG, PM ;
FRISHMAN, WH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (11) :1023-1038
[2]   Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate [J].
Farthing, D ;
Sica, D ;
Fakhry, I ;
Pedro, A ;
Gehr, TWB .
JOURNAL OF CHROMATOGRAPHY B, 1997, 704 (1-2) :374-378
[3]   SIMULTANEOUS DETERMINATION OF A NOVEL ANGIOTENSIN-II RECEPTOR BLOCKING-AGENT, LOSARTAN, AND ITS METABOLITE IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
FURTEK, CI ;
LO, MW .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 573 (02) :295-301
[4]   Pharmacological profiles of a novel non-peptide angiotensin II type I receptor antagonist HR720 in vitro and in vivo [J].
Jin, D ;
Song, K ;
Oka, Y ;
Takai, S ;
Shiota, N ;
Miyazaki, M .
JAPANESE JOURNAL OF PHARMACOLOGY, 1997, 75 (03) :259-266
[5]   Effects of losartan on cerebral and ocular circulation in healthy subjects [J].
Matulla, B ;
Streit, G ;
Pieh, S ;
Findl, O ;
Entlicher, J ;
Graselli, U ;
Eichler, HG ;
Wolzt, M ;
Schmetterer, L .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (04) :369-375
[6]   An elective-titration study of the comparative effectiveness of two angiotensin II receptor blockers, irbesartan and losartan [J].
Oparil, S ;
Guthrie, R ;
Lewin, AJ ;
Marbury, T ;
Reilly, K ;
Triscari, J ;
Witcher, JA .
CLINICAL THERAPEUTICS, 1998, 20 (03) :398-409
[7]   An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection [J].
Ritter, MA ;
Furtek, CI ;
Lo, MW .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1997, 15 (07) :1021-1029
[8]   HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP3174 in biological material of humans and rats [J].
Soldner, A ;
Spahn-Langguth, H ;
Mutschler, E .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 16 (05) :863-873
[9]   Clinical safety and tolerability of losartan [J].
Weber, M .
CLINICAL THERAPEUTICS, 1997, 19 (04) :604-616